Maprotiline Ameliorates High Glucose-Induced Dysfunction in Renal Glomerular Endothelial Cells.
Cells, Cultured
Diabetic Nephropathies
/ metabolism
Endothelial Cells
/ metabolism
Glucose
/ pharmacology
Humans
Kidney Glomerulus
/ metabolism
Maprotiline
/ metabolism
Oxidative Stress
Prostaglandin-Endoperoxide Synthases
/ metabolism
Protein Kinase C-alpha
/ metabolism
RNA, Messenger
/ metabolism
Reactive Oxygen Species
/ metabolism
Superoxide Dismutase
/ metabolism
Thromboxane B2
/ metabolism
Journal
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
ISSN: 1439-3646
Titre abrégé: Exp Clin Endocrinol Diabetes
Pays: Germany
ID NLM: 9505926
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
pubmed:
24
3
2022
medline:
21
9
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
Maprotiline is an antidepressant that has been found to cause hypoglycemia. However, the effect of maprotiline on diabetic nephropathy (DN) has not been investigated. Here, we explored the effect of maprotiline on human renal glomerular endothelial cells (HRGECs) in response to high glucose (HG) stimulation. We found that maprotiline attenuated HG-induced oxidative stress in HRGECs with decreased reactive oxygen species production and increased superoxide dismutase activity. Maprotiline repressed the HG-induced expression of cyclooxygenases 2 at both mRNA and protein levels in HRGECs. The increased thromboxane B2 level and decreased 6-keto-prostaglandin F1α level induced by HG were significantly attenuated by maprotiline treatment. Maprotiline also prevented the HG-induced increase in the permeability of HRGECs and the decrease in the zonula occludens-1 expression and downregulated HG-induced increase in the expression of protein kinase C-α (PKC-α) in HRGECs. This protective effect of maprotiline on HG-induced HRGECs dysfunction was abolished by overexpression of PKC-α. In conclusion, maprotiline displayed a protective effect on HG-challenged HRGECs, which was mediated by the regulation of PKC-α. These findings provide further evidence for the potential use of maprotiline for the treatment of DN.
Substances chimiques
RNA, Messenger
0
Reactive Oxygen Species
0
Maprotiline
2U1W68TROF
Thromboxane B2
54397-85-2
Prostaglandin-Endoperoxide Synthases
EC 1.14.99.1
Superoxide Dismutase
EC 1.15.1.1
Protein Kinase C-alpha
EC 2.7.11.13
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
596-603Subventions
Organisme : 20158294
ID : Hainan Provincial Natural Science Foundation
Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.